Pseudomyxoma Peritonei Long Term Survival and Prognosis
Study of 2300 PMP Cases: Long Term Survival
An international array of surgical oncology researchers, including Terence C. Chua, Brendan J. Moran, Paul H. Sugarbaker, Edward Allen Levine, Olivier Glehen, Francois N. Gilly, Dominique Elias, Dario Baratti, Marcello Deraco, Armando Sardi, David L. Morris, established a multi institutional registry in affiliation with the Peritoneal Surface Oncology Group International (PSOGI) to study the effects of CRS and HIPEC on nearly 2,300 Pseudomyxoma Peritonei patients.
“The median survival was 196 months or 16.3 years. The median progression-free survival (PFS) was 98 months or 8.2 years, with a 10- and 15-year survival rate of 63% and 59% respectively.”
Click here to review the abstract from this collaborative effort.
Presented at ASCO, 01.20.12
PMP Pals' Network: Resources, Referrals, Research and Support!
Ken lives an active life following treatment for Appendiceal Cancer with Pseudomyxoma Peritonei Syndrome!
Become a "PMP Pal" and communicate directly with Ken!
This week's article of interest...
Cancer Survivors: A Booming Population
This abstract focuses on the growing number of survivors and population aging, and the impact these combined trends will have on cancer survivorship in the future.
Source: Julia H. Rowland, National Cancer Institute/NIH, Office of Cancer Survivorship, Division of Cancer Control and Population Sciences, 6116 Executive Boulevard, Suite 404, Bethesda, MD 20892. Phone: 301-402-2746; Fax: 301-594-5070; E-mail: rowlandj@mail.nih.gov
Pseudomyxoma Peritonei Prognosis and Long Term Survival Rate
What is the long term prognosis for Pseudomyxoma Peritonei?
The doctor says I have "PMP." What is my prognosis?
What is the prognosis for "PMP?"
What are the long term survival statistics for Pseudomyxoma Peritonei?
What is the long term survival rate for Pseudomyxoma Peritonei?
Can I outlive the survival statistics for Pseudomyxoma Peritonei?
The prognosis and survival for Pseudomyxoma Peritonei, and Appendiceal Cancer , in general, has improved during the past decade, with earlier detection, enhanced education of healthcare providers, including radiologists and pathologists, followed by referrals to specialists and improved methods of treatment.
Many factors contribute to the prognosis and long term survival of patients. These factors may include pathology, staging at the time of diagnosis, overall health of the patient at the time of the diagnosis, age at the time of diagnosis, access to specialized care, etc.
Long term survival may increase with early and accurate diagnosis, overall health of the patient at the time of diagnosis, the actual pathology/diagnosis itself, and appropriate treatment provided by a specialist.
Patients are encouraged not to accept the original dismal prognosis that may initially be offered by a non specialist.
Each case is unique and each patient is an individual. Published statistics do not reflect the unique case of a newly diagnosed patient, whose options for long term survival are continually improving through modern medical treatment.
Communicate with any of our Pal Mentors who have been disease free from five to twenty years!
One patient's story of hope!
Read articles about our cancer free "Pals!"
Read "Cancer Patients Can Outlive Statistics" by PMP Pals
Read survival stories from our fellow "Pals!"
This week's featured medical report:
Upfront Compared to Delayed Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Is Associated With Considerably Lower Perioperative Morbidity and Recurrence Rate. Chua TC, Liauw W, Zhao J, Morris DL.
*UNSW Department of Surgery, St George Hospital, Kogarah, Sydney, Australia. †Department of Medical Oncology, Cancer Care Centre, St George Hospital, Kogarah, Sydney, Australia.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) is a recognized management strategy for pseudomyxoma peritonei. We seek to evaluate the outcomes of patients treated upfront with CRS PIC compared to patients undergoing delayed CRS PIC as salvage or treatment for recurrences after initial debulking surgery.
METHODS: Retrospective analysis of patients with low-grade pseudomyxoma peritonei treated within our institution were stratified according to upfront versus delayed CRS PIC after intial debulking surgery. Survival was analyzed using the Kaplan-Meier method and compared using the log-rank test.
RESULTS: Of 83 patients treated, 35 patients (42%) underwent upfront and 48 patients (58%) underwent delayed CRS PIC. The peritoneal cancer index (P = 0.048), amount of blood transfusion intraoperatively (P = 0.003) and duration of operation (P = 0.007) was lesser in the upfront compared to delayed group. Upfront treatment confers 5-year recurrence-free survival benefit (77% vs 37%; P = 0.011) and 10-year overall survival benefit (67% vs 35%; P = 0.054) over delayed treatment.
CONCLUSION: Upfront CRS PIC seems to confer beneficial perioperative outcomes and lower recurrence rates over delayed CRS PIC. Early referral to centralized treatment centers would seem to be a reasonable strategy to improve outcomes. Source: Annals of Surgical Oncology, Jan 13, 2011
Here are a selection of medical journal excerpts and reports providing specific details about the prognosis and long term survival statistics for Pseudomyxoma Peritonei.
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; the French Surgical Association.
Cancer. 2010 Aug 24. [Epub ahead of print]PMID: 20737573 [PubMed - as supplied by publisher]
Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation.
Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL.
J Am Coll Surg. 2010 Aug 20. [Epub ahead of print]PMID: 20729102 [PubMed - as supplied by publisher]
[Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis.]
Lim C, Tordjmann D, Gornet JM, Nemeth J, Valleur P, Pocard M.
Bull Cancer. 2010 Aug 6. [Epub ahead of print] French. PMID: 20693116 [PubMed - as supplied by publisher]Related citations
The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome.
Brouquet A, Goéré D, Lefèvre JH, Bonnet S, Dumont F, Raynard B, Elias D.
Ann Surg Oncol. 2009 Oct;16(10):2744-51. Epub 2009 Jul 21.PMID: 19626375 [PubMed - indexed for MEDLINE]Related citations
Survival of patients with pseudomyxoma peritonei treated by serial debulking.
Järvinen P, Järvinen HJ, Lepistö A.
Colorectal Dis. 2010 Sep;12(9):868-72. Epub 2009 Jun 10.PMID: 19519686 [PubMed - in process]Related citations
.Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL.
Ann Surg Oncol. 2009 Jul;16(7):1903-11. Epub 2009 Apr 23.PMID: 19387742 [PubMed - indexed for MEDLINE]Related citations
Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M.
Ann Surg. 2009 Feb;249(2):243-9.PMID: 19212177 [PubMed - indexed for MEDLINE]Related citations
Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei.
Chua TC, Yan TD, Yap ZL, Horton MD, Fermanis GG, Morris DL.
J Surg Oncol. 2009 Apr 1;99(5):292-5.PMID: 19180588 [PubMed - indexed for MEDLINE]Related citations
Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy.
Reuter NP, Macgregor JM, Woodall CE, Sticca RP, William C, Helm MB, Scoggins CR, McMasters KM, Martin RC.
Am J Surg. 2008 Dec;196(6):909-13; discussion 913-4.PMID: 19095108 [PubMed - indexed for MEDLINE]Related citations
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei).
Moran B, Baratti D, Yan TD, Kusamura S, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):277-82. Review.PMID: 18726894 [PubMed - indexed for MEDLINE]Related citations
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, AU
This report describes the long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience. This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
Pseudomyxoma Peritonei
Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
Conclusions: The morbidity and mortality outcomes of CRS and HIPEC are similar to a major gastrointestinal surgery, such as a Whipple's procedure. To derive the maximal benefit of this treatment, careful patient selection with an optimal level of postoperative care must be advocated to avoid undesirable complications of this treatment.
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris, 2009
12 Year Study of CRS and HIPEC for Pseudomyxoma Peritonei Treatment
Source: In Vivo, 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital
Appendiceal Mucinous Neoplasms: Study Analysis Predicting Recurrance
Source: American Journal of Surgical Pathology, 2009
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
Appendix Cancer Prognosis
Source: Dr Paul Sugarbaker, Washington Hospital Center
Appendiceal Adenocarcinoma: Long Term Outcome After Surgery
Source: Harvard Medical School, 2004
Morbidity and Mortality Study for Pseudomyxoma Peritonei following CRS and HIPEC
Source: Pseudomyxoma Peritonei Center, Hampshire, June 2009
Pseudomyxoma Peritonei Prognosis following serial debulking (long term study)
Source: Helskinki Univ Central Hospital, Finland, June 2009
Pseudomyxoma Peritonei Prognosis for VEGH expression patients with Mucinous Adenocarcinoma of the Appendix
Source: Annals of Surgical Oncology 2008
Pseudomyxoma Peritonei Prognosis following Chemo Hyperthermic Profusion
Source: Fukai School of Medicine, Japan, April 2009
Pseudomyxoma Peritonei prognosis: biologic features affecting prognosis
Source: Annals of Surgical Oncology 2009
Pseudomyxoma Peritonei prognosis and survival following surgery and HIPEC
Source: Pub Med, Feb 2009
Pseudomyxoma Peritonei prognosis and survival evaluating tumor markers following surgery and HIPEC
Source: Annals of Surgical Oncology, 2008
Pseudomyxoma Peritonei prognosis following HIPEC treatment
Source: ASCO 2007
Pseudomyxoma Peritonei and Peritonei Carcinomatosis Prognosis Indicators
Source: Pub Med 2005
Pseudomyxoma Peritonei Treatment: Library of Medical Publications
Source: Pub Med 2009
Appendix Cancer Library including Pseudomyxoma Peritonei Treatment and Prognosis: Multiple Medical Publications
Source: Pub Med 2009
Analysis of 46 Pseudomyxoma Peritonei patients' prognosis following "second look" surgery
Source: Dr Paul Sugarbaker 2000
Cancer Survivorship
The Survivors' Club
Source: Ben Sherwood, author
What is the long term prognosis for Pseudomyxoma Peritonei?
The doctor says I have "PMP." What is my prognosis?
What is the prognosis for "PMP?"
What are the long term survival statistics for Pseudomyxoma Peritonei?
What is the long term survival rate for Pseudomyxoma Peritonei?
Can I outlive the survival statistics for Pseudomyxoma Peritonei?
The prognosis and survival for Pseudomyxoma Peritonei, and Appendiceal Cancer , in general, has improved during the past decade, with earlier detection, enhanced education of healthcare providers, including radiologists and pathologists, followed by referrals to specialists and improved methods of treatment.
Many factors contribute to the prognosis and long term survival of patients. These factors may include pathology, staging at the time of diagnosis, overall health of the patient at the time of the diagnosis, age at the time of diagnosis, access to specialized care, etc.
Long term survival may increase with early and accurate diagnosis, overall health of the patient at the time of diagnosis, the actual pathology/diagnosis itself, and appropriate treatment provided by a specialist.
Patients are encouraged not to accept the original dismal prognosis that may initially be offered by a non specialist.
Each case is unique and each patient is an individual. Published statistics do not reflect the unique case of a newly diagnosed patient, whose options for long term survival are continually improving through modern medical treatment.
Communicate with any of our Pal Mentors who have been disease free from five to twenty years!
One patient's story of hope!
Read articles about our cancer free "Pals!"
Read "Cancer Patients Can Outlive Statistics" by PMP Pals
Read survival stories from our fellow "Pals!"
This week's featured medical report:
Upfront Compared to Delayed Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Is Associated With Considerably Lower Perioperative Morbidity and Recurrence Rate. Chua TC, Liauw W, Zhao J, Morris DL.
*UNSW Department of Surgery, St George Hospital, Kogarah, Sydney, Australia. †Department of Medical Oncology, Cancer Care Centre, St George Hospital, Kogarah, Sydney, Australia.
Abstract
BACKGROUND: Cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) is a recognized management strategy for pseudomyxoma peritonei. We seek to evaluate the outcomes of patients treated upfront with CRS PIC compared to patients undergoing delayed CRS PIC as salvage or treatment for recurrences after initial debulking surgery.
METHODS: Retrospective analysis of patients with low-grade pseudomyxoma peritonei treated within our institution were stratified according to upfront versus delayed CRS PIC after intial debulking surgery. Survival was analyzed using the Kaplan-Meier method and compared using the log-rank test.
RESULTS: Of 83 patients treated, 35 patients (42%) underwent upfront and 48 patients (58%) underwent delayed CRS PIC. The peritoneal cancer index (P = 0.048), amount of blood transfusion intraoperatively (P = 0.003) and duration of operation (P = 0.007) was lesser in the upfront compared to delayed group. Upfront treatment confers 5-year recurrence-free survival benefit (77% vs 37%; P = 0.011) and 10-year overall survival benefit (67% vs 35%; P = 0.054) over delayed treatment.
CONCLUSION: Upfront CRS PIC seems to confer beneficial perioperative outcomes and lower recurrence rates over delayed CRS PIC. Early referral to centralized treatment centers would seem to be a reasonable strategy to improve outcomes. Source: Annals of Surgical Oncology, Jan 13, 2011
Here are a selection of medical journal excerpts and reports providing specific details about the prognosis and long term survival statistics for Pseudomyxoma Peritonei.
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1290 patients.
Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D; the French Surgical Association.
Cancer. 2010 Aug 24. [Epub ahead of print]PMID: 20737573 [PubMed - as supplied by publisher]
Secondary Cytoreduction and Perioperative Intraperitoneal Chemotherapy after Initial Debulking of Pseudomyxoma Peritonei: A Study of Timing and the Impact of Malignant Dedifferentiation.
Chua TC, Al-Zahrani A, Saxena A, Liauw W, Zhao J, Morris DL.
J Am Coll Surg. 2010 Aug 20. [Epub ahead of print]PMID: 20729102 [PubMed - as supplied by publisher]
[Prospective study of quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy using oxaliplatin for peritoneal carcinomatosis.]
Lim C, Tordjmann D, Gornet JM, Nemeth J, Valleur P, Pocard M.
Bull Cancer. 2010 Aug 6. [Epub ahead of print] French. PMID: 20693116 [PubMed - as supplied by publisher]Related citations
The second procedure combining complete cytoreductive surgery and intraperitoneal chemotherapy for isolated peritoneal recurrence: postoperative course and long-term outcome.
Brouquet A, Goéré D, Lefèvre JH, Bonnet S, Dumont F, Raynard B, Elias D.
Ann Surg Oncol. 2009 Oct;16(10):2744-51. Epub 2009 Jul 21.PMID: 19626375 [PubMed - indexed for MEDLINE]Related citations
Survival of patients with pseudomyxoma peritonei treated by serial debulking.
Järvinen P, Järvinen HJ, Lepistö A.
Colorectal Dis. 2010 Sep;12(9):868-72. Epub 2009 Jun 10.PMID: 19519686 [PubMed - in process]Related citations
.Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
Chua TC, Yan TD, Smigielski ME, Zhu KJ, Ng KM, Zhao J, Morris DL.
Ann Surg Oncol. 2009 Jul;16(7):1903-11. Epub 2009 Apr 23.PMID: 19387742 [PubMed - indexed for MEDLINE]Related citations
Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Baratti D, Kusamura S, Nonaka D, Cabras AD, Laterza B, Deraco M.
Ann Surg. 2009 Feb;249(2):243-9.PMID: 19212177 [PubMed - indexed for MEDLINE]Related citations
Thoracic cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy for pseudomyxoma peritonei.
Chua TC, Yan TD, Yap ZL, Horton MD, Fermanis GG, Morris DL.
J Surg Oncol. 2009 Apr 1;99(5):292-5.PMID: 19180588 [PubMed - indexed for MEDLINE]Related citations
Preoperative performance status predicts outcome following heated intraperitoneal chemotherapy.
Reuter NP, Macgregor JM, Woodall CE, Sticca RP, William C, Helm MB, Scoggins CR, McMasters KM, Martin RC.
Am J Surg. 2008 Dec;196(6):909-13; discussion 913-4.PMID: 19095108 [PubMed - indexed for MEDLINE]Related citations
Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei).
Moran B, Baratti D, Yan TD, Kusamura S, Deraco M.
J Surg Oncol. 2008 Sep 15;98(4):277-82. Review.PMID: 18726894 [PubMed - indexed for MEDLINE]Related citations
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital,Univ of New South Wales, Sydney, AU
This report describes the long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience. This report demonstrates long-term survival outcomes, acceptable perioperative outcomes, and a learning curve associated with the treatment of patients with pseudomyxoma peritonei.
Pseudomyxoma Peritonei
Biological Features Are the Dominant Prognostic Determinants After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Source: Annals of Surgery, Dr Marcello Deraco, Dr Baratti, 2009
Morbidity and Mortality: Study of HIPEC and CRS for Treatment of Peritoneal Carcinomatosis
Source: Annals of Surgery, Feb 2009, Dr David Morris, Dr Tristan Yan
Conclusions: The morbidity and mortality outcomes of CRS and HIPEC are similar to a major gastrointestinal surgery, such as a Whipple's procedure. To derive the maximal benefit of this treatment, careful patient selection with an optimal level of postoperative care must be advocated to avoid undesirable complications of this treatment.
DPAM: Peritonectomy Improves Survival
Source Prof David L Morris, 2009
12 Year Study of CRS and HIPEC for Pseudomyxoma Peritonei Treatment
Source: In Vivo, 2009
DPAM Long Term Survival
Source: Dr BM Ronnett, Dr Paul H Sugarbaker, 2009
Pseudomyxoma Peritonei Long Term Survival (10 year study)
Source: Annals of Surgical Oncology, 2009, Prof David L Morris, St George Hospital
Appendiceal Mucinous Neoplasms: Study Analysis Predicting Recurrance
Source: American Journal of Surgical Pathology, 2009
CRS with HIPEC have improved quality and quantity of life for patients
Source:Dr Brian Loggie, 2007
Survival Study for Pseudomyxoma Peritonei: DPAM, PMCA, PMCA 1
Source: Dr Edward Levine, American Journal of Surgical Pathology, May 2006
Appendix Cancer Prognosis
Source: Dr Paul Sugarbaker, Washington Hospital Center
Appendiceal Adenocarcinoma: Long Term Outcome After Surgery
Source: Harvard Medical School, 2004
Morbidity and Mortality Study for Pseudomyxoma Peritonei following CRS and HIPEC
Source: Pseudomyxoma Peritonei Center, Hampshire, June 2009
Pseudomyxoma Peritonei Prognosis following serial debulking (long term study)
Source: Helskinki Univ Central Hospital, Finland, June 2009
Pseudomyxoma Peritonei Prognosis for VEGH expression patients with Mucinous Adenocarcinoma of the Appendix
Source: Annals of Surgical Oncology 2008
Pseudomyxoma Peritonei Prognosis following Chemo Hyperthermic Profusion
Source: Fukai School of Medicine, Japan, April 2009
Pseudomyxoma Peritonei prognosis: biologic features affecting prognosis
Source: Annals of Surgical Oncology 2009
Pseudomyxoma Peritonei prognosis and survival following surgery and HIPEC
Source: Pub Med, Feb 2009
Pseudomyxoma Peritonei prognosis and survival evaluating tumor markers following surgery and HIPEC
Source: Annals of Surgical Oncology, 2008
Pseudomyxoma Peritonei prognosis following HIPEC treatment
Source: ASCO 2007
Pseudomyxoma Peritonei and Peritonei Carcinomatosis Prognosis Indicators
Source: Pub Med 2005
Pseudomyxoma Peritonei Treatment: Library of Medical Publications
Source: Pub Med 2009
Appendix Cancer Library including Pseudomyxoma Peritonei Treatment and Prognosis: Multiple Medical Publications
Source: Pub Med 2009
Analysis of 46 Pseudomyxoma Peritonei patients' prognosis following "second look" surgery
Source: Dr Paul Sugarbaker 2000
Cancer Survivorship
The Survivors' Club
Source: Ben Sherwood, author
Thank you to our Pal Sponsors!
This web page is sponsored by our Pals, Bob and Misty!
Visitors to www.pmppals.org are encouraged to discuss publications and information contained herein with their licensed, professional healthcare providers. The information provided on www.pmppals.org is not intended as a replacement for licensed, professional medical or legal advice.
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright 2012 by PMP Pals' Network/All rights reserved. Updated 01.25.12
Please respect your fellow patients and caregivers by not copying or cutting and pasting any pages from this website onto yours.
The PMP Pals Network is a volunteer patient advocacy program. We support the services that we provide, including this web page, as volunteers and through subscriptions to our publications.
We neither solicit nor receive funds from pharmaceutical companies or healthcare providers, thus maintaining our dedication to serving as patient advocates.
Individuals or organizations who plagiarize this copyrighted website will be prosecuted.
Copyright 2012 by PMP Pals' Network/All rights reserved. Updated 01.25.12
